Mr William C Cirillo, MD | |
90 E. Stevens St, Camilla, GA 31730 | |
(229) 336-4621 | |
(229) 336-4682 |
Full Name | Mr William C Cirillo |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 90 E. Stevens St, Camilla, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831291228 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 025531 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr William C Cirillo, MD 90 E Stephens St, P. O. Box 639, Camilla, GA 31730-1836 Ph: (229) 336-4621 | Mr William C Cirillo, MD 90 E. Stevens St, Camilla, GA 31730 Ph: (229) 336-4621 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.
Researchers at the University of Pennsylvania School of Medicine have discovered that using an immune system gene to enhance a vaccine used to study HIV in macaque monkeys provides the animals with greater protection against simian HIV (SHIV) than an unmodified vaccine.
A-Life Medical, Inc., the pioneer and leading provider of computer-assisted coding products and services to the healthcare industry, announced today the forging of an exclusive agreement with the oldest and largest independently owned radiology group in Ohio, Cleveland-based Drs. Hill & Thomas Co.
Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).
› Verified 6 days ago